Emergent BioSolutions outlines $720M–$760M 2026 revenue target as transformation plan advances [Seeking Alpha]
Emergent Biosolutions, Inc. (EBS)
Last emergent biosolutions, inc. earnings: 4/30 04:08 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.emergentbiosolutions.com
Company Research
Source: Seeking Alpha
CEO Joseph Papa stated that "over the past 2 years, our Emergent team has made substantial progress executing on our multiyear transformation plan, strengthening our financial position through great operating results, strategic divestitures, margin Quick Insights Emergent BioSolutions expects 2026 revenues of $720–$760 million, with adjusted EBITDA of $135–$155 million and adjusted net income between $25 million and $45 million. Transformation efforts resulted in a 12% rise in adjusted EBITDA, a 900 basis point gross margin improvement, and net leverage reduction from 3.3x to 1.9x. Key risks include no repeat of a $60 million international order, pricing and seasonality in naloxone, and uncertainties from U.S. government shutdown impacts. Recommended For You More Trending News
Show less
Read more
Impact Snapshot
Event Time:
EBS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EBS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EBS alerts
High impacting Emergent Biosolutions, Inc. news events
Weekly update
A roundup of the hottest topics
EBS
News
- Emergent Biosolutions (EBS) was downgraded by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from "hold (c-)" to "sell (d+)".MarketBeat
- Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors [Yahoo! Finance]Yahoo! Finance
- Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of DirectorsGlobeNewswire
- Emergent Biosolutions Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- Emergent BioSolutions Inc (EBS) Q4 2025 Earnings Call Highlights: Strategic Gains Amid Revenue ... [Yahoo! Finance]Yahoo! Finance
EBS
Earnings
- 10/29/25 - Beat
EBS
Analyst Actions
- 12/16/25 - HC Wainwright
EBS
Sec Filings
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- EBS's page on the SEC website